ArticleThe Journal of clinical endocrinology and metabolism2024
Novel Detection and Progression Markers for Diabetes Based on Continuous Glucose Monitoring Data Dynamics.
Article in The Journal of clinical endocrinology and metabolism, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
27 citing papers in PubMed.
- Continuous glucose monitoring using the FreeStyle Libre Pro iQ in presymptomatic type 1 diabetes.Diabetologia · 2026Article
- Article
- Continuous Glucose Monitoring and Mortality Risk Among U.S. Veterans Receiving Dialysis With Diabetes.Diabetes care · 2026Article
- Reproducibility of continuous glucose monitoring-derived postprandial glucose features and their association with glycemic control in type 2 diabetes.Nutrition & diabetes · 2026Article
- Article
- Time to resolution of diabetic ketoacidosis in children with type 1 diabetes: a survival analysis of clinical predictors.BMC endocrine disorders · 2026Article
- Machine learning evaluation of TyG-based metrics for arteriosclerosis progression.Scientific reports · 2026Article
- Expanding Access to Early Diabetes Detection: A Pharmacy-Based Screening Pilot in Rural New South Wales.Health science reports · 2026Article
- Metabolic determinants of torque teno virus load across the diabetes spectrum: insights from a cross-sectional analysis.Scientific reports · 2026Article
- Continuous glucose monitoring-based evaluation of percentage coefficient of variation (%CV) as a metric of intraday glycemic variability in South India.Scientific reports · 2026Article
- Re-evaluating heart rate variability biomarkers for glucose sensing: the impact of age normalisation and subject-independent validation.BMC medical informatics and decision making · 2026Article
- Lack of Association Between Hemoglobin A1c and Continuous Glucose Monitor Metrics Among Individuals with Prediabetes and Normoglycemia.Diabetes technology & therapeutics · 2026Article
- Differences in Continuous Glucose Monitoring Metrics Between Prediabetes and Normoglycemia: A Systematic Review and Meta-Analysis.Journal of diabetes science and technology · 2026Review
- Changes in tactile acuity and their association with balance impairment in type 2 diabetes: A 2-year cohort study.Diabetology & metabolic syndrome · 2026Article
- Risk Factors for Hypoglycemia in Type 2 Diabetes Mellitus Patients Using Once-Weekly Semaglutide: A Matched Case-Control Study.Therapeutics and clinical risk management · 2026Article
- Improving non-invasive glucose estimation with monthly calibrated photoplethysmography and implicit HbA1c.Communications medicine · 2025Article
- Nationwide implementation of a diabetes self-management and network system improves outcomes in type 1 diabetes: real-world evidence from Thailand.BMC endocrine disorders · 2025Observational
- Glucodensity functional profiles outperform traditional continuous glucose monitoring metrics.Scientific reports · 2025Article
- Evaluating Insulin Delivery Systems Using Dynamic Glucose Region Plots and Risk Space Analysis.Sensors (Basel, Switzerland) · 2025Article
- Predictive value of obesity-related indices for incident type 2 diabetes mellitus: a longitudinal study of the Fukushima Health Database 2015-2021.Diabetology & metabolic syndrome · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
contextStatic measures of continuous glucose monitoring (CGM) data, such as time spent in specific glucose ranges (70-180 mg/dL or 70-140 mg/dL), do not fully capture the dynamic nature of blood glucose, particularly the subtle gradual deterioration of glycemic control over time in individuals with early-stage type 1 diabetes.
objectiveDevelop a diabetes diagnostic tool based on 2 markers of CGM dynamics: CGM entropy rate (ER) and Poincaré plot (PP) ellipse area (S).
methodsA total of 5754 daily CGM profiles from 843 individuals with type 1, type 2 diabetes, or healthy individuals with or without islet autoantibody status were used to compute 2 individual dynamic markers: ER (in bits per transition; BPT) of daily probability matrices describing CGM transitions between 8 glycemic states, and the area S (mg2/dL2) of individual CGM PP ellipses using standard PP descriptors. The Youden index was used to determine "optimal" cut-points for ER and S for health vs diabetes (case 1); type 1 vs type 2 (case 2); and low vs high type 1 immunological risk (case 3). The markers' discriminative power was assessed through the area under the receiver operating characteristics curves (AUC).
resultsOptimal cutoff points were determined for ER and S for each of the 3 cases. ER and S discriminated case 1 with AUC = 0.98 (95% CI, 0.97-0.99) and AUC = 0.99 (95% CI, 0.99-1.00), respectively (cutoffs ERcase1 = 0.76 BPT, Scase1 = 1993.91 mg2/dL2), case 2 with AUC = 0.81 (95% CI, 0.77-0.84) and AUC = 0.76 (95% CI, 0.72-0.81), respectively (ERcase2 = 1.00 BPT, Scase2 = 5112.98 mg2/dL2), and case 3 with AUC = 0.72 (95% CI, 0.58-0.86), and AUC = 0.66 (95% CI, 0.47-0.86), respectively (ERcase3 = 0.52 BPT, Scase3 = 923.65 mg2/dL2).
conclusionCGM dynamics markers can be an alternative to fasting plasma glucose or glucose tolerance testing to identify individuals at higher immunological risk of progressing to type 1 diabetes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.